Mary Wilson
Well-known member
Published: February 10, 2021
DOI: https://doi.org/10.1016/j.medj.2021.02.001
Natalia Sherina [SUP]15 ,[/SUP]Antonio Piralla [SUP]15 ,[/SUP]Likun Du [SUP]15 ,[/SUP]Hui Wan [SUP]15 ,[/SUP]Makiko Kumagai-Braesch, Juni Andr?ll,Sten Braesch-Andersen, Irene Cassaniti, Elena Percivalle, Antonella Sarasini, Federica Bergami, Raffaella Di Martino, Marta Colaneri, Marco Vecchia, Margherita Sambo, Valentina Zuccaro, Raffaele Bruno, Michele Sachs, Tiberio Oggionni, Federica Meloni, Hassan Abolhassani, Federico Bertoglio, Maren Schubert, Miranda Byrne-Steele, Jian Han, Michael Hust, Yintong Xue [SUP]16, [/SUP]Lennart Hammarstr?m [SUP]16, [/SUP]Fausto Baldanti [SUP]16, [/SUP]Harold Marcotte [SUP]16, [/SUP]Qiang Pan-Hammarstr?m [SUP]16[/SUP][SUP], [/SUP][SUP]17[/SUP]
Highlights
Anti-SARS-CoV-2 antibodies were present in 85% of the samples collected within 4 weeks after onset of symptoms in COVID-19 patients. Levels of specific IgM/IgA antibodies declined after 1 month while levels of specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG antibodies were still present, though at a significantly lower level, in 80% of the samples collected at 6-8 months after symptom onset. SARS-CoV-2-specific memory B- and T-cell responses developed with time and were persistent in all patients followed up till 6-8 months.
Graphical Abstract
https://www.cell.com/med/fulltext/S2666-6340(21)00038-6
PDF format:
Journal Pre-proof
https://www.cell.com/action/showPdf?pii=S2666-6340(21)00038-6
DOI: https://doi.org/10.1016/j.medj.2021.02.001
Natalia Sherina [SUP]15 ,[/SUP]Antonio Piralla [SUP]15 ,[/SUP]Likun Du [SUP]15 ,[/SUP]Hui Wan [SUP]15 ,[/SUP]Makiko Kumagai-Braesch, Juni Andr?ll,Sten Braesch-Andersen, Irene Cassaniti, Elena Percivalle, Antonella Sarasini, Federica Bergami, Raffaella Di Martino, Marta Colaneri, Marco Vecchia, Margherita Sambo, Valentina Zuccaro, Raffaele Bruno, Michele Sachs, Tiberio Oggionni, Federica Meloni, Hassan Abolhassani, Federico Bertoglio, Maren Schubert, Miranda Byrne-Steele, Jian Han, Michael Hust, Yintong Xue [SUP]16, [/SUP]Lennart Hammarstr?m [SUP]16, [/SUP]Fausto Baldanti [SUP]16, [/SUP]Harold Marcotte [SUP]16, [/SUP]Qiang Pan-Hammarstr?m [SUP]16[/SUP][SUP], [/SUP][SUP]17[/SUP]
Highlights
- •
Anti-SARS-CoV-2 antibodies were present in the majority of COVID-19 patient samples - •
RBD- and S-specific IgG levels remained stable up to 6 months after diagnosis - •
Specific memory B- and T-cells developed in >95% of COVID-19 patients - •
Memory B- and T-cell responses were maintained at least 6-8 months after infection
Anti-SARS-CoV-2 antibodies were present in 85% of the samples collected within 4 weeks after onset of symptoms in COVID-19 patients. Levels of specific IgM/IgA antibodies declined after 1 month while levels of specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG antibodies were still present, though at a significantly lower level, in 80% of the samples collected at 6-8 months after symptom onset. SARS-CoV-2-specific memory B- and T-cell responses developed with time and were persistent in all patients followed up till 6-8 months.
Graphical Abstract
https://www.cell.com/med/fulltext/S2666-6340(21)00038-6
PDF format:
Journal Pre-proof
https://www.cell.com/action/showPdf?pii=S2666-6340(21)00038-6